This technological breakthrough has paved the way for mRNA therapeutics beyond vaccines, enabling applications in genetic, metabolic, and cardiovascular diseases
It is a safety directive based on the molecular structure of the medication itself
, 47 , 102145, Sun, Q., Mehl, S., Renko, K., Seemann, P., Gorlich, C
Fusions with the [G 4 S] 3 A linker to the antibody light chain displayed potent GLP-1R activation (EC 50 : 100300 pM) whilst PCSK9 binding activity decreased by 2-70-fold relative to the parental anti-PCSK9 antibodies
However, the direct effects of GLP-1RAs, independent of weight loss, were not statistically significant [49]
It's worth noting that 5 mg is an approved maintenance dose, not a microdose, so the trial speaks to reduced therapeutic dosing rather than to microdosing